Breaking RepliCel (OTCQB: $REPCF; TSX: $RP.V) @RepliCel News; US Patent Issued to for its Novel Dermal Injection Technologies
With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market
VANCOUVER, BC – April 25, 2017 - (Investorideas.com Newswire) . (OTCQB: REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel” or the “Company”), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions, today announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) covering significant components of the Company’s novel, multi-needle dermal injection device.